Indication

For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise:

  • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • In combination with other medicinal products for the treatment of diabetes

Medicine details

Medicine name:
semaglutide (Rybelsus)
SMC ID:
SMC2287
Pharmaceutical company
Novo Nordisk Ltd
BNF chapter
Endocrine system
Submission type
Abbreviated
Publication due date:
07 September 2020